RA
ARNA

Royce & Associates’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Royce & Associates’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-981
Closed -$41K – 1245
2020
Q1 		$41K Sell
981
-117
-11% -$5.36K ﹤0.01% 1034
2019
Q4 		$50K Sell
1,098
-18
-2% -$851 ﹤0.01% 1041
2019
Q3 		$51K Buy
1,116
+455
+69% +$25.6K ﹤0.01% 1048
2019
Q2 		$39K Buy
+661
New +$34.2K ﹤0.01% 1053

Other funds holding ARNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Royce & Associates's ARNA Position: Q2 2020 in Review

Royce & Associates sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2020, closing a stake of 981 shares — an estimated $41K sold.

Royce & Associates first reported a position in ARNA in Q2 2019 and held it in 4 quarters. The position peaked at $51K in Q3 2019. 247 funds tracked by Wall St. Rank hold ARNA as of Q2 2020.

  • Royce & Associates reported no remaining Arena Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Royce & Associates sold 981 Arena Pharmaceuticals Inc shares in Q2 2020, an estimated $41K.
  • Royce & Associates first reported a position in Arena Pharmaceuticals Inc in Q2 2019 and held it in 4 quarters.
  • Royce & Associates's Arena Pharmaceuticals Inc position peaked at $51K in Q3 2019.
  • 247 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2020.

Based on Royce & Associates's 13F filing for Q2 2020, filed 7 Aug 2020.